Matrixx Initiatives Inc – FDA 483, May 28, 2009
On May 26 and May 28, 2009, the FDA inspected Matrixx Initiatives Inc., a drug manufacturer located at 8515 E Anderson Dr, Scottsdale, AZ 85255-5461. The inspection was conducted by Investigator Timothy T Kapsala, and the report was issued to Tim L. Clarot, Vice President R&D and Product Quality.
The sole observation noted was that serious adverse events for a non-prescription drug used in the United States had not been reported to the Secretary. Specifically, the firm did not classify and report anosmia (loss of smell) or loss of taste as serious adverse events, and consequently, these complaints were not reported to the Food and Drug Administration's MedWatch reporting system. Three specific complaints, AE09-000723, AE09-000736, and AE09-000886, were identified as not having been reported.
- Company
- Matrixx Initiatives Inc
- Inspection date
- May 28, 2009
- Product type
- Drugs
ID · 13e58331-582e-4d97-8f70-d6e90e17dc02
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.